ABSTRACT
BACKGROUND: Recent studies have demonstrated that microRNA-22 (miR-22) was deregulated in many types of cancers and was involved in various cellular processes related to carcinogenesis. However, the clinical significance and prognostic value of miR-22 in epithelial ovarian cancer (EOC) haven't been investigated. METHODS: 109 pairs of fresh EOC tissue and matched adjacent normal tissue specimens were collected between May 2007 and March 2013. Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-22. The chi-square test was used to assess miR-22 expression with respect to clinicopathological parameters. The survival curves of the patients were determined using the Kaplan-Meier method and Cox regression, and the log-rank test was used for statistical evaluations. RESULTS: miR-22 expression in EOC tissues was significantly lower than that in matched normal adjacent tissues (mean ± SD: 1.944 ± 1.026 vs. 4.981 ± 1.507, P<0.0001). Low miR-22 expression level was correlated with FIGO stage (P=0.006), tumor grade (P=0.03), and lymph node metastases (P=0.01). Kaplan-Meier analysis with the log-rank test indicated that low miR-22 expression had a significant impact on overall survival (44.4% vs. 64.5%; P=0.005) and progression-free survival (23.5% vs. 52.6%; P=0.004). CONCLUSIONS: Our data demonstrated that the expression of miR-22 was downregulated in EOC, and associated with overall survival as well as progression-free survival, suggesting that miR-22 could serve as an efficient prognostic factor for EOC patients. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_178.
Subject(s)
Biomarkers, Tumor/genetics , Down-Regulation/genetics , MicroRNAs/genetics , Neoplasms, Glandular and Epithelial/diagnosis , Ovarian Neoplasms/diagnosis , Biomarkers, Tumor/metabolism , Chi-Square Distribution , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Kaplan-Meier Estimate , MicroRNAs/metabolism , Middle Aged , Neoplasms, Glandular and Epithelial/genetics , Neoplasms, Glandular and Epithelial/metabolism , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovary/metabolism , Ovary/pathology , Prognosis , Retrospective StudiesABSTRACT
The purpose of this study was to explore the expression of ATAD2 in ovarian tumor tissue as well as its relationship with degree of malignancy. Tumor tissue from 110 cases of ovarian cancer was collected in accordance with the Declaration of Helsinki for evaluation of ATAD2 expression immunohistochemistry, quantitative PCR (qPCR) and Western blotting. The correlation between the ATAD2 expression and and the prognosis of ovarian cancer was evaluated by Cox regression model. In addition, HO-8910 and OVCAR-3 cells were transfected with two siRNAs targeting ATAD2. Cell viability was evaluated with MTT assay, and cell migration by transwell migration assay. ATAD2 was shown to be highly expressed in 65.5% (72/110) of ovarian cancer cases, both at transcriptional and protein levels. Moreover, highly expression was positively correlated with degree of malignancy. Knock-down of ATAD2 in HO-8910 and OVCAR-3 cells was found to reduce cell migration. In addition, follow-up visits of the patients demonstrated that the 5-year survival rate was lower in patients with high expression of ATAD2. Our study suggested that ovarian tumor tissue may have highly expressed ATAD2, which is associated with tumor stage, omentum-metastasis, ascites and CA-125. Increased ATAD2 may play important roles in tumor proliferation and migration. ATAD2 could serve in particular as a prognostic marker and a therapeutic target for ovarian cancer.
Subject(s)
Adenocarcinoma, Mucinous/metabolism , Adenosine Triphosphatases/metabolism , Cystadenocarcinoma, Serous/metabolism , DNA-Binding Proteins/metabolism , Omentum/metabolism , Ovarian Neoplasms/metabolism , ATPases Associated with Diverse Cellular Activities , Adenocarcinoma, Mucinous/mortality , Adenocarcinoma, Mucinous/secondary , Adenosine Triphosphatases/antagonists & inhibitors , Adenosine Triphosphatases/genetics , Blotting, Western , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/secondary , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/genetics , Female , Follow-Up Studies , Humans , Immunoenzyme Techniques , Lymphatic Metastasis , Middle Aged , Neoplasm Staging , Omentum/pathology , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , RNA, Messenger/genetics , RNA, Small Interfering/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Survival Rate , Tumor Cells, CulturedABSTRACT
OBJECTIVE: To discuss the value of grey scale ultrasonography and color Doppler of bi-planar transrectal ultrasound on the diagnosis of hyperplasia prostate gland (HPG). METHODS: One hundred and ninety-two patients with HPG and 50 control subjects underwent abdominal ultrasound and TRUS examinations. The width (W), depth (D) and length (L) of the prostates and transitional zones were respectively measured. Each transitional zone index (TZI), i.e., the ratio of the transitional zone volume to the total prostate volume was calculated. Meanwhile, we observed the blood flow distribution in the prostates, calculated the parameters of hemodynamics such as peak systolic velocity (PSV), resistance index (RI) and pulse index (PI), and analyzed their correlations with TZI. RESULTS: The revealing rates of cystic formation, calcium calculus and ejaculatory cyst and PSV, RI of arterial vessels in HPG were all significantly higher in the HPG patients than in the control subjects, and the revealing rates of all the above pathological changes but calcium calculus by TRUS were significantly higher than by abdominal examination. TZI of HPG was positively correlated with PSV, RI and PI. CONCLUSION: Bi-planar TRUS can clearly display the normal and pathological structure of the prostate. And PSV, RI and PI may aid in the diagnosis of HPG and the assessment of the degree of prostatic proliferation.
Subject(s)
Prostatic Hyperplasia/diagnostic imaging , Adolescent , Adult , Aged , Aged, 80 and over , Humans , Male , Middle Aged , Prostate/blood supply , Prostate/diagnostic imaging , Prostate/pathology , Prostatic Hyperplasia/pathology , Regional Blood Flow , Ultrasonography, Doppler, Color/methodsABSTRACT
BACKGROUND & OBJECTIVE: c-jun is an early protooncogene and its protein product is a component of activating protein-1 (AP-1) transcription factor. c-jun participates in the transcription of many growth factors and cytokines. Recently it has been found that the expression level and activity of c-jun protein in tumor cells abnormally increased and c-jun protein controlled the proliferation, surviving, and apoptosis of tumor cells. In this study, the expression of c-jun protein in laryngeal cancer and its relationship with clinical statistics were discussed to evaluate the controlling role of c-jun protein in laryngeal cancer. METHODS: Samples from Department of Otolaryngology, The First Affiliated Hospital of China Medical University, were acquired from May 2001 to February 2002. These samples including 52 laryngeal cancer tissues, 15 vocal polyps, and 10 normal laryngeal tissues were investigated individually by immunohistochemistry to observe the localization and expression of c-jun protein in these three kinds of samples. RESULTS: The expression of c-jun protein in laryngeal cancer (56.41+/-24.8%) was not only significantly higher than that in vocal cord (32.48+/-1.78%) and laryngeal tissue (no expression), but also was correlated with the differentiating degree of laryngeal cancer tissue and lymph node metastasis(P< 0.01); however, the expression of c-jun was not associated with clinical staging(P >0.05). CONCLUSION: The expression level of c-jun protein significantly increased in laryngeal cancer cell and its expression may be considered as an indicator for differentiating degree,neck lymph node metastasis, and prognosis of laryngeal cancer.
